Precigen PGEN
NASDAQ PGEN
$7.11 -0.03 (-0.49%)
As of: Sep 4, 2026 · 3:59 PM EDT

Precigen (PGEN) Free Cash Flow (2012 - 2026)

Precigen (PGEN) posted quarterly Free Cash Flow of -$44.0 million for Q1 2026, down 159.78% year-over-year from $73.6 million in Q1 2025, and down 87.52% quarter-over-quarter from -$23.5 million in Q4 2025.

Analysis

Precigen (PGEN) Free Cash Flow (2012 - 2026) Analysis & Trends

Precigen (PGEN) has reported Free Cash Flow for 15 consecutive years, with -$44.0 million the latest figure, recorded in Q1 2026.

  • In Q1 2026, Free Cash Flow fell 159.78% year-over-year to -$44.0 million; the TTM figure through Mar 2026 stood at -$116.9 million (down 74.43% YoY), while the FY2025 annual figure was -$89.8 million, down 31.11% from the prior year.
  • Free Cash Flow declined to -$44.0 million in Q1 2026 per PGEN's latest filing, from -$23.5 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$1.0 million in Q4 2024 and bottomed at -$44.0 million in Q1 2026.
  • Historically, Free Cash Flow has averaged -$20.0 million across 5 years, with a median of -$18.4 million in 2024.
  • Annual changes were most pronounced in 2024 — Free Cash Flow soared 93.51% — and 2025, when it plunged 2183.85%.
  • Precigen's Free Cash Flow stood at -$15.4 million in 2022, then dropped by 2.54% to -$15.8 million in 2023, then jumped by 93.51% to -$1.0 million in 2024, then slumped by 2183.85% to -$23.5 million in 2025, then tumbled by 87.52% to -$44.0 million in 2026.
  • Business Quant data shows PGEN's Free Cash Flow at -$44.0 million in Q1 2026, -$23.5 million in Q4 2025, and -$30.8 million in Q3 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Free Cash Flow (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 1.01 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 572.80 Mn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn -563.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn - -389.61 Mn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 437.80 Mn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 292.04 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn - 477.44 Mn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn -95.09 Mn
10 Precigen 2.53 Bn 2.53 Bn 52.17 Mn -18.20 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -18.20 Mn
Mar 31, 2026 -44.09 Mn
Dec 31, 2025 -23.48 Mn
Sep 30, 2025 -29.46 Mn
Jun 30, 2025 -19.70 Mn
Mar 31, 2025 -17.19 Mn
Dec 31, 2024 -9.27 Mn
Sep 30, 2024 -23.62 Mn
Jun 30, 2024 -25.43 Mn
Mar 31, 2024 -18.44 Mn
Dec 31, 2023 -16.53 Mn
Sep 30, 2023 -17.53 Mn
Jun 30, 2023 -15.87 Mn
Mar 31, 2023 -18.54 Mn
Dec 31, 2022 -15.45 Mn
Sep 30, 2022 -25.39 Mn
Jun 30, 2022 -8.77 Mn
Mar 31, 2022 -20.36 Mn
Dec 31, 2021 -17.36 Mn
Sep 30, 2021 -19.29 Mn